



Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

OPEN ACCESS

Approved by:

Frontiers Production Office,
Frontiers Media SA, Switzerland

*Correspondence:

Frontiers Production Office
production.office@frontiersin.org

Specialty section:

This article was submitted to
Pharmacology of Infectious Diseases,
a section of the journal
Frontiers in Pharmacology

Received: 23 June 2022

Accepted: 23 June 2022

Published: 18 August 2022

Citation:

Frontiers Production Office (2022)
Erratum: Cefiderocol for the Treatment
of Multidrug-Resistant Gram-Negative
Bacteria: A Systematic Review of
Currently Available Evidence.
Front. Pharmacol. 13:976792.
doi: 10.3389/fphar.2022.976792

Frontiers Production Office *

Frontiers Media SA, Lausanne, Switzerland

Keywords: cefiderocol, multidrug resistant, carbapenem-resistant, gram-negative bacteria, systematic review

An Erratum on

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

by Wang C, Yang D, Wang Y and Ni W (2022). *Front. Pharmacol.* 13:896971. doi: 10.3389/fphar.2022.896971

Due to a production error, the Funding statement was not provided. The correct Funding statement is as follows: This work was supported by the National Natural Science Foundation of China (81903672), Peking University People's Hospital Research and Development Funds (RS2020-04), and China International Medical Foundation (Z-2018-35-2003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The publisher apologizes for this mistake. The original version of this article has been updated. Your article has been copyedited to ensure that we publish the highest quality work possible. Please check it carefully to make sure that it is correct and that the meaning was not lost during the process.

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.